z-logo
open-access-imgOpen Access
Outcomes of three intravitreal injections of bevacizumab given monthly for diabetic macular oedema is a viable treatment for an economically disadvantaged population
Author(s) -
Aazambir S. Brar,
Vivek B. Wani,
Arvind L. Tenagi
Publication year - 2021
Publication title -
african vision and eye health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.186
H-Index - 5
eISSN - 2413-3183
pISSN - 2410-1516
DOI - 10.4102/aveh.v80i1.618
Subject(s) - medicine , bevacizumab , ophthalmology , visual acuity , diabetic retinopathy , endophthalmitis , ranibizumab , population , diabetic macular edema , diabetes mellitus , surgery , chemotherapy , environmental health , endocrinology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom